Summary & Overview

CPT 0492U: CellSearch PD–L1 Circulating Tumor Cell Test

CPT code 0492U designates the CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test, a Proprietary Laboratory Analyses (PLA) code that describes a manufacturer-specific blood-based assay to select circulating tumor cells and quantify PD–L1 expression. The code matters nationally as an emerging companion diagnostic approach for assessing tumor PD–L1 status via liquid biopsy, with implications for immunotherapy selection, disease monitoring, and precision oncology workflows. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn the clinical purpose and laboratory setting for the test, payer coverage considerations, and operational details relevant to billing and specimen handling. The publication summarizes what the code represents, where the service is typically performed, and which major national payers are relevant to coverage discussions. It also outlines common modifiers and where to locate additional documentation for a proprietary assay. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0492UCPTproprietary laboratory analysiscirculating tumor cellsPD-L1liquid biopsyoncology diagnosticsmolecular pathologyCellSearch

Billing Code Overview

CPT code 0492U is a Proprietary Laboratory Analyses (PLA) code that applies only to the CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test from Menarini Silicon Biosystems Inc. The test uses circulating tumor cell (CTC) selection and biomarker analysis to identify and quantify PD–L1 expression on tumor cells in blood, providing a liquid-biopsy assessment of tumor PD–L1 status.

Service Type: Proprietary laboratory molecular/biomarker analysis of circulating tumor cells

Typical Site of Service: Clinical laboratory or specialized diagnostic laboratory; sample collection typically occurs in an outpatient phlebotomy or clinical setting

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with a history of metastatic non-small cell lung cancer (NSCLC) undergoing systemic therapy presents for biomarker monitoring. The oncology team orders a CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test to quantify PD‑L1 expression on circulating tumor cells from a peripheral blood draw to help characterize tumor biology and potentially inform treatment selection or clinical trial eligibility. Blood is collected in appropriate anticoagulant tubes and sent to the Menarini Silicon Biosystems Inc. laboratory or an authorized facility. The lab performs CTC selection and immunophenotypic analysis, reports the number of CTCs and PD‑L1 expression metrics. Results are returned to the ordering oncologist, who incorporates the findings into the overall clinical assessment and treatment planning. Typical site of service is an outpatient phlebotomy clinic, oncology infusion center, or hospital outpatient department where blood collection and specimen transport are available.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Standard reporting when no special circumstance applies
`26`	Professional component	When only the professional component (interpretation) is billed separately

Taxonomy Code	Specialty	Notes
207Q00000X	Medical Oncology	Primary ordering specialty for CTC PD‑L1 testing
207L00000X	Hematology	May order or interpret circulating cell analyses
208D00000X	Diagnostic Radiology	May assist with image‑guided vascular access for complex blood draws
261QM0800X	Clinical Laboratory	Laboratory directors and pathologists overseeing processing and reporting
207K00000X	Surgical Oncology	May order testing for surgical oncology patients for systemic therapy planning

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	NSCLC is a common indication for PD‑L1 testing on tissue or CTCs to inform therapy selection
`C50.912`	Malignant neoplasm of unspecified site of right female breast	Breast cancer with metastatic disease can be evaluated with CTC assays for biomarker expression
`C71.9`	Malignant neoplasm of brain, unspecified	Metastatic or primary CNS tumors may prompt circulating biomarker testing in select contexts
`C79.51`	Secondary malignant neoplasm of bone	Metastatic disease monitoring via CTCs can aid in systemic disease characterization
`C78.7`	Secondary malignant neoplasm of liver	Liver metastases are common in multiple solid tumors where CTC biomarker assessment may be utilized

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Typical specimen collection method performed before sending sample for the CTC PD‑L1 test
`81025`	Urine pregnancy test, performed in laboratory, qualitative	Often ordered for reproductive‑aged patients before initiating certain systemic therapies; may be part of pre‑treatment lab panel
`88384`	Immunohistochemistry (IHC) with further interpretation and report, per single antigen/antibody stain	Related technique for tissue PD‑L1 assessment; complements blood‑based PD‑L1 testing in workflow
`86328`	Protein; C‑reactive protein (CRP), high sensitivity	Example ancillary laboratory marker; not specific but commonly ordered in oncology monitoring panels
`0000U`	Proprietary laboratory analysis (example PLA)	Other PLA codes may be billed for proprietary molecular or cellular assays in the same workflow (use specific code for the test performed)